Whitehawk Therapeutics Inc WHWK
News
Whitehawk Therapeutics Presents Real-World Analyses Supporting MUC16 as a Durable ADC Target in Ovarian Cancer at IGCS 2026
Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026
Whitehawk Therapeutics Appoints Vijay Iyengar, MD, to Board of Directors
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
